Robust cross-neutralizing antibody responses but variable cellular immunity following either Comirnaty and Spikevax JN.1-adapted mRNA vaccination in the elderly.

Saved in:
Bibliographic Details
Title: Robust cross-neutralizing antibody responses but variable cellular immunity following either Comirnaty and Spikevax JN.1-adapted mRNA vaccination in the elderly.
Authors: Tang YS; The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: samtang@cuhk.edu.hk., Chen C; The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: chunkechen@cuhk.edu.hk., Lv H; Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA; Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. Electronic address: huibinlv@illinois.edu., Sun Y; The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: yuanxinsun@cuhk.edu.hk., Tan CW; Program in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore; Infectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: cheewah.tan@duke-nus.edu.sg., Yiu K; Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: ysyiu@cuhk.edu.hk., Ling KC; Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: kenlingkc@cuhk.edu.hk., Chan KKP; Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: chankapang@cuhk.edu.hk., Mok CKP; The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; SH Ho Research Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: kapunmok@cuhk.edu.hk., Hui DS; Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; SH Ho Research Centre for Emerging Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: dschui@cuhk.edu.hk.
Source: Vaccine [Vaccine] 2026 Jun 11; Vol. 83, pp. 128634. Date of Electronic Publication: 2026 Apr 29.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2026.128634